Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
US9801860B2 · kind B2 · utility
1Cited by
17References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 18, 2015 |
| Grant date | Oct 31, 2017 |
| Priority date | — |
| Expiry date | Nov 18, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.